Views Article – Sharenet Wealth

Europe, News

Drugmaker Hikma to buy U.S.-based Custopharm to boost needle-based treatments

(Adds detail on deal, background)

Sept 27 (Reuters) – Hikma Pharmaceuticals said on Monday it would buy U.S.-based sterile injectables firm Custopharm in a deal worth up to $425 million, as the generic medicines maker looks to strengthen its needle-based treatments unit in the United States.

Hikma makes drugs including anaesthetics, pain medications, sedatives, neuromuscular agents and anti-infectives. The demand for these drugs shot up during the pandemic and remains strong as elective surgeries return.

“With this acquisition, Hikma will have a differentiated US portfolio of close to 130 injectable medicines – a more than fivefold increase over the last decade,” said Riad Mishlawi, president of the injectables division.

The company expects Custopharm to generate more than $80 million in sales this year and boost margins of its injectables business.

Hikma in August forecast annual core operating margin in the range of 37% to 38% for its injectables business.

The London-based company said it would pay $375 million in cash and the deal would include an additional $50 million in the form of milestone-based payments. It bought Custopharm from Chicago-based Water Street Healthcare Partners.

Shares of Hikma were up 1.5% at 2,421 pence by 0707 GMT. (Reporting by Aditi Sebastian and Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty)


© 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.